Hydrocortisone Pharmis

Hydrocortisone Pharmis is an injectable solution containing hydrocortisone sodium succinate. It is supplied in a sterile liquid for intramuscular or intravenous use and is marketed in the EU as prescription‑only. The product provides a rapid rise in plasma cortisol levels, facilitating management of adrenal insufficiency and severe inflammatory states. It is indicated for emergency replacement therapy and is administered by healthcare professionals in hospital or clinic settings.

Hydrocortisone Pharmis is employed in situations that require rapid systemic glucocorticoid activity.

- Acute adrenal crisis and other forms of adrenal insufficiency. - Severe inflammatory or allergic reactions unresponsive to other therapy. - Management of shock states where cortisol deficiency contributes to hemodynamic instability. - Peri‑operative stress dosing in patients with known adrenal insufficiency. - Treatment of certain severe dermatologic or rheumatologic emergencies when oral therapy is impractical. - Replacement therapy in patients receiving chronic glucocorticoid suppression who cannot take oral medication.

Adverse reactions to Hydrocortisone Pharmis may vary in frequency and severity.

Common: - Transient hyperglycemia, especially in patients with diabetes. - Mild electrolyte disturbances such as mild hyponatremia or hypokalemia. - Local injection site reactions including pain, erythema, or swelling. - Headache or dizziness during rapid infusion.

Serious: - Severe allergic reactions, including anaphylaxis or angioedema. - Acute adrenal suppression after abrupt discontinuation. - Significant infection risk due to immunosuppression, manifesting as pneumonia or sepsis. - Gastrointestinal bleeding or ulceration, particularly with concurrent NSAID use. - Psychiatric disturbances such as mood swings, depression, or psychosis.

When prescribing Hydrocortisone Pharmis, clinicians should consider several precautionary measures to minimize risk.

- Assess baseline cortisol levels and adrenal function before initiating therapy. - Use the lowest effective dose and limit duration to reduce systemic side effects. - Monitor blood glucose and electrolytes, particularly in patients with diabetes or renal impairment. - Avoid abrupt discontinuation; taper the dose gradually to prevent adrenal crisis. - Evaluate for active infections, as glucocorticoids can exacerbate them. - Caution in pregnant or breastfeeding women; benefits must outweigh potential risks. - Review patient history for hypersensitivity to corticosteroids.

Hydrocortisone Pharmis can interact with other medicines, influencing efficacy or safety.

Avoid: - Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce glucocorticoid levels. - Simultaneous administration of other systemic corticosteroids, which can increase the risk of additive adverse effects.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or anticoagulants, which may raise the risk of gastrointestinal bleeding. - Live vaccines, because immunosuppression can diminish vaccine efficacy. - Antidiabetic agents, as glucocorticoids may worsen hyperglycemia. - Antihypertensive drugs, particularly ACE inhibitors or diuretics, due to potential electrolyte shifts.